European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting

• Date:
  Pátek, 3 Březen 2023, All day
• Místo konání:
  Online
  European Medicines Agency, Amsterdam, the Netherlands

The Patients' and Consumers’ (PCWP) and Healthcare Professionals’ (HCPWP) Working Parties will meet on 3 March 2023.

The meeting will focus on the following topics:

• reorganisation of EMA Working parties;
• feedback from EMA scientific committees;
• medical device expert panels;
• biosimilars and interchangeability;
• EMA policy for multilingualism.

Documents

Agenda - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting

Draft Reference Number: EMA/836371/2022

Meeting summary - European Medicines Agency (EMA) Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties joint meeting

Reference Number: EMA/89221/2023

Presentation - Reorganisation of EMA working parties - A. Ganan Jimenez (EMA)

Presentation - The Scientific Advice Working Party (SAWP) and its interaction with other WPs and groups - I. Gravanis (EMA)

Presentation - Methodology Working Party - A. Thomson (EMA)

Presentation - CHMP/CVMP 3Rs Working party (3RsWP) - S. Ponzano (EMA)

Presentation - Highlights on the Committee for Advanced Therapies - M. de Lemus Belmonte (CAT)

Presentation - PCWP/HCPWP feedback from CHMP - F. Ventura and C. Prieto (CHMP)

Presentation - PCWP/HCPWP feedback from COMP - E. Rook and T. Leest (COMP)

Presentation - PCWP/HCPWP feedback from HMPC - O. Palomino and A. Lê (HMPC)

Presentation - PCWP/HCPWP feedback from PDCO - J. Taminiau (PDCO)

Presentation - Medical Device Regulation - M. Antunes (EMA)

Presentation - ACT EU Multistakeholder platform concept paper consultation and kick-off meeting - M. Filancia (EMA)

Presentation - Biosimilar Breakout Session : HMA-EMA Multi-stakeholder workshop on shortages - S. Thirstrup and R. Gonzalez-Quevedo (EMA)

Presentation - Interchangeability of biosimilars: Joint EMA-HMA statement - R. Gonzalez-Quevedo (EMA)

Presentation - Campaigns - M. Benstetter (EMA)

Presentation - Multilingualism on the EMA website and in external communications - M. Benstetter (EMA)

Video recordings

Reorganisation of EMA Working Parties

 
SAWP – interaction with other WPs

 
Methodology Working Party

 
3 Rs Working Party

 
CAT Feedback

 
CHMP Feedback

 
COMP Feedback

 

HMPC Feedback

 
PDCO Feedback

 
Medical Device Regulation

ACT EU Multistakeholder platform: concept paper consultation and kick-off meeting

 

Update and report from Shortage workshop breakout session

EMA's statement on interchangeability of biosimilars

 
Feedback on mini campaigns

Multilingualism on the EMA website and in externa communications – a new policy